Nexavar Expansion Plans Suffer Another Blow With Failed Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer.